Main prospective studies of PBSCT consolidation in first-line MCL
| Regimen . | Reference (year) . | N . | 3-year EFS, % . | 3-year OS, % . | Main toxicity . |
|---|---|---|---|---|---|
| Hyper-CVAD/HD-MTX-Ara-C | Khouri et al50 (1998) | 25 | 72 | 92 | — |
| Khouri et al59 (2003) | 31 | 43% at 5 years | 77% at 5 years | — | |
| 3 × APO + rituximab + sequential high-dose | Gianni et al62 (2003) | 28 | 80 | 90 | 18% CMV reactivation |
| CHOP + HD-CVB + rituximab | Mangel et al63 (2004) | 20 | 89 | 88 | Interstitial pneumonitis |
| 6xCHOP + HDdexaBEAM | Dreyling et al60 (2005) | 62 | 54 | 83 | 5% toxic deaths |
| CTAP/VMAC + HD-BuCy | Evens et al64 (2007) | 25 | 50 | 60 | |
| CHOP+HD-Ara-C +HD-R-Cy-TBI | Dreger et al65 (2007) | 34 | 80 | 100 | 79% severe mucositis |
| R-maxi-CHOP +R-HD-Ara-C+R-BEAM | Geisler et al61 (2008) | 160 | 70 | 85 | 5% toxic deaths |
| Regimen . | Reference (year) . | N . | 3-year EFS, % . | 3-year OS, % . | Main toxicity . |
|---|---|---|---|---|---|
| Hyper-CVAD/HD-MTX-Ara-C | Khouri et al50 (1998) | 25 | 72 | 92 | — |
| Khouri et al59 (2003) | 31 | 43% at 5 years | 77% at 5 years | — | |
| 3 × APO + rituximab + sequential high-dose | Gianni et al62 (2003) | 28 | 80 | 90 | 18% CMV reactivation |
| CHOP + HD-CVB + rituximab | Mangel et al63 (2004) | 20 | 89 | 88 | Interstitial pneumonitis |
| 6xCHOP + HDdexaBEAM | Dreyling et al60 (2005) | 62 | 54 | 83 | 5% toxic deaths |
| CTAP/VMAC + HD-BuCy | Evens et al64 (2007) | 25 | 50 | 60 | |
| CHOP+HD-Ara-C +HD-R-Cy-TBI | Dreger et al65 (2007) | 34 | 80 | 100 | 79% severe mucositis |
| R-maxi-CHOP +R-HD-Ara-C+R-BEAM | Geisler et al61 (2008) | 160 | 70 | 85 | 5% toxic deaths |
CMV indicates cytomegalovirus.